MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Fundamental Analysis

TSX:MBX • CA59501P1045

0.24 CAD

0 (0%)

Last: Feb 27, 2026, 07:00 PM

Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

Fundamental Rating

Overall MBX gets a fundamental rating of 4 out of 10. We evaluated MBX against 24 industry peers in the Biotechnology industry. While MBX seems to be doing ok healthwise, there are quite some concerns on its profitability. MBX has a correct valuation and a medium growth rate.

Quickly go to:

1. Profitability 2. Health 3. Growth 4. Valuation 5. Dividend

1. Profitability

1.1 Basic Checks

In the past year MBX has reported negative net income.
In the past year MBX has reported a negative cash flow from operations.
In multiple years MBX reported negative net income over the last 5 years.
In multiple years MBX reported negative operating cash flow during the last 5 years.

1.2 Ratios

The Return On Assets of MBX (-6.00%) is better than 86.36% of its industry peers.
With an excellent Return On Equity value of -8.08%, MBX belongs to the best of the industry, outperforming 86.36% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-6%
ROE	-8.08%
ROIC	N/A

ROA(3y)1.04%

ROA(5y)3.95%

ROE(3y)1.4%

ROE(5y)5.76%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Gross Margin value of 53.02%, MBX belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
In the last couple of years the Gross Margin of MBX has grown nicely.
MBX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	53.02%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-3.11%

GM growth 5Y3.66%

More info and screens

ROA ROE ROIC Operating and Profit Margin Show most profitable peers

2. Health

2.1 Basic Checks

MBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MBX has more shares outstanding
Compared to 5 years ago, MBX has more shares outstanding
The debt/assets ratio for MBX is higher compared to a year ago.

2.2 Solvency

MBX has an Altman-Z score of 1.76. This is a bad value and indicates that MBX is not financially healthy and even has some risk of bankruptcy.
MBX's Altman-Z score of 1.76 is fine compared to the rest of the industry. MBX outperforms 77.27% of its industry peers.
A Debt/Equity ratio of 0.24 indicates that MBX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.24, MBX perfoms like the industry average, outperforming 54.55% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.24
Debt/FCF	N/A
Altman-Z	1.76

ROIC/WACCN/A

WACC7.57%

2.3 Liquidity

A Current Ratio of 8.48 indicates that MBX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 8.48, MBX belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
A Quick Ratio of 5.17 indicates that MBX has no problem at all paying its short term obligations.
The Quick ratio of MBX (5.17) is better than 86.36% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	8.48
Quick Ratio	5.17

More info and screens

WACC Debt/Equity How to determine the health of a company Altman-Z score Show peers with great health

3. Growth

3.1 Past

The earnings per share for MBX have decreased strongly by -163.28% in the last year.
Looking at the last year, MBX shows a very negative growth in Revenue. The Revenue has decreased by -26.81% in the last year.
MBX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.05% yearly.

EPS 1Y (TTM)-163.28%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-440.62%

Revenue 1Y (TTM)-26.81%

Revenue growth 3Y-0.87%

Revenue growth 5Y12.05%

Sales Q2Q%-40.51%

3.2 Future

MBX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.75% yearly.
MBX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.96% yearly.

EPS Next Y33.33%

EPS Next 2Y52.75%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year35.93%

Revenue Next 2Y29.96%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

MBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 5.94, the valuation of MBX can be described as very cheap.
Based on the Price/Forward Earnings ratio, MBX is valued cheaper than 95.45% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of MBX to the average of the S&P500 Index (28.05), we can say MBX is valued rather cheaply.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	5.94

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, MBX is valued cheaply inside the industry as 95.45% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	145.76

4.3 Compensation for Growth

MBX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as MBX's earnings are expected to grow with 52.75% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y52.75%

EPS Next 3YN/A

More info and screens

Price/Earnings Price/FCF FCF per share EV/EBITDA PEG RATIO Show best valued peers

5. Dividend

5.1 Amount

MBX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks Show peers with best dividend

MICROBIX BIOSYSTEMS INC

TSX:MBX (2/27/2026, 7:00:00 PM)

0.24

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)02-12 2026-02-12

Earnings (Next)05-13 2026-05-13

Inst Owners0.43%

Inst Owner ChangeN/A

Ins Owners14.76%

Ins Owner ChangeN/A

Market Cap33.25M

Revenue(TTM)18.59M

Net Income(TTM)-2.25M

Analysts80

Price Target0.51 (112.5%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-44.44%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	5.94
P/S	1.79
P/FCF	N/A
P/OCF	N/A
P/B	1.2
P/tB	1.38
EV/EBITDA	145.76

EPS(TTM)-0.02

EYN/A

EPS(NY)0.04

Fwd EY16.83%

FCF(TTM)-0.01

FCFYN/A

OCF(TTM)0

OCFYN/A

SpS0.13

BVpS0.2

TBVpS0.17

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-6%
ROE	-8.08%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	53.02%
FCFM	N/A

ROA(3y)1.04%

ROA(5y)3.95%

ROE(3y)1.4%

ROE(5y)5.76%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-3.11%

GM growth 5Y3.66%

F-Score2

Asset Turnover0.5

Health

		Industry Rank	Sector Rank
Debt/Equity	0.24
Debt/FCF	N/A
Debt/EBITDA	34.25
Cap/Depr	44.81%
Cap/Sales	4.29%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	8.48
Quick Ratio	5.17
Altman-Z	1.76

F-Score2

WACC7.57%

ROIC/WACCN/A

Cap/Depr(3y)83.66%

Cap/Depr(5y)119.48%

Cap/Sales(3y)5.99%

Cap/Sales(5y)7.06%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-163.28%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-440.62%

EPS Next Y33.33%

EPS Next 2Y52.75%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-26.81%

Revenue growth 3Y-0.87%

Revenue growth 5Y12.05%

Sales Q2Q%-40.51%

Revenue Next Year35.93%

Revenue Next 2Y29.96%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-139.08%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year4.01%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-135.95%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-101.85%

OCF growth 3YN/A

OCF growth 5YN/A

MICROBIX BIOSYSTEMS INC / MBX.CA FAQ

What is the ChartMill fundamental rating of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MBX.CA.

What is the valuation status of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?

ChartMill assigns a valuation rating of 5 / 10 to MICROBIX BIOSYSTEMS INC (MBX.CA). This can be considered as Fairly Valued.

What is the profitability of MBX stock?

MICROBIX BIOSYSTEMS INC (MBX.CA) has a profitability rating of 3 / 10.